Sukmo Kang, D.V.M., Ph.D. graduated from Seoul National University and received his doctorate in KAIST (Korean Advanced Institute of Science and Technology). He is majored in nanotech-based vaccine engineering and developed new strategies for delivering vaccine antigens and adjuvants.
Since he joined Biotoxtech groups, he has given consults for non-clinical development of new modality drugs and DDS technology-applied drugs. He has hold the director position of Biotoxtech, Keyfronbio and Keyprime research and is in charge of overall research planning and business development of BTT groups.
Since he joined Biotoxtech groups, he has given consults for non-clinical development of new modality drugs and DDS technology-applied drugs. He has hold the director position of Biotoxtech, Keyfronbio and Keyprime research and is in charge of overall research planning and business development of BTT groups.
Speaking In
4:45 PM - 5:00 PM (PDT)
Monday, June 13
BTT Groups, head-quartered in Korea, are the global non-clinical service providers composed of…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
